Entero Therapeutics, Inc. announced on August 11, 2025, that it has entered into definitive agreements with institutional investors for a private placement totaling approximately $3.0 million.
The offering involves the sale of 4,878,841 pre-funded warrants and 9,757,682 common warrants. The combined purchase price for one pre-funded warrant and two common warrants is $0.6149.
Approximately $1.0 million of the gross proceeds will be received at closing, with the remaining $2.0 million contingent upon the effectiveness of a resale registration statement. The company expects to use these net proceeds for general corporate purposes and working capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.